Uso de testosterona transdérmica em mulheres no menacme com desejo sexual hipoativo e qualidade de vida: ensaio clínico randomizado duplo-cego

• Autor(a) principal: Margato, Marcela Furlan [UNIFESP]
• Data de Publicação: 2020
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=10028030; https://hdl.handle.net/11600/64829
• topic: Testosterone; Quality Of Life; Women; Libido; Depression; Skin Cream; Testosterona; Qualidade De Vida; Mulheres; Libido; Depressão; Creme Para A Pele

BACKGROUND: Although several studies have been using transdermal testosterone, associated or not with estrogen therapy, as one of the treatments for the complaint of Hypoactive Sexual Desire Disorder (HSDD), there is still no consensus on its use in menacme, on effective dose, side effects or whether, in fact, there are positive results on the increase in libido. Several studies have also shown an improvement in quality of life, neurological cognition, general well-being and an improvement in depression in the populations studied with the use of testosterone replacement therapy. OBJECTIVE: To evaluate the effects of a nanostructured transdermal testosterone cream in the treatment of HSDD on the impact on quality of life, general well-being and sexuality, as well as its side effects, within 12 weeks in women at menacme. METHODOLOGY: Women (n = 52) with complaints of low sexual desire at the UNIFESP Endocrine Gynecology clinic were screened according to the inclusion and exclusion criteria. Participants were divided into two previously randomized groups, blood samples were collected for laboratory tests, completed the FSFI (Female Sexual Function Index) questionnaires, Beck's Depression Inventory (IDB) and WHOQOL-bref (shortened quality of life questionnaire). life and well-being) before and after the start of treatment, and were instructed to make daily use of the prescribed formulation (vehicle Biolipid with placebo or Biolipid with Testosterone 300mcg) according to the group to which they belonged. Participants and researchers remained blind until the end of the study of resultsPatients diagnosed with HSDD at UNIFESP Gynecology Clinic were screened according to the inclusion and exclusion criteria. Participants (n = 52) were divided into two groups randomly, blood samples were collected for laboratory tests, they completed the FSFI (Female Sexual Function Index) questionnaire, Beck's Depression Inventory (IDB) and WHOQOL-bref (short World Health Organization Quality of Life) before and after the start of treatment, and were xi instructed to make daily use of the vehicle formulation Biolipid with placebo or Biolipid with Testosterone 300mcg according to the group to which they belonged. As participants and researchers remained blind until the final analysis of the results. RESULTS: Group B (group that used the formulation containing testosterone 300mcg / puff) showed a significant increase in the scores of the FSFI desire, arousal, lubrication, orgasm, satisfaction and pain domains, this improvement being more evident in young patients. The placebo group also showed improvement, but with slightly less expressive results. Both groups showed improvement regarding depressive symptoms. There was a tendency to increase androgen dosages in group B, but without statistical difference. There was no significant change in quality of life and no serious side effects were observed. CONCLUSION: The formulation of Biolipid vehicle with Testosterone 300mcg transdermally showed positive effects on sexuality and symptoms of depression, without negative effects on quality of life, keeping plasma androgen levels within the normal range, although further studies are needed.